Unidentified Analyst: This is actually Destiny on for Jeff. I will start by kind of continuing on the last group of questions. I’m curious, how are you determining the initial physicians that will be welcomed into your demo sites? And is this going to be more of a group demonstration? Or is this going to be on a kind of one-to-one basis?
Erez Meltzer: First of all, right now, as we have shared, it’s — actually, it’s a full range. So we have individuals that are coming to see the systems and will be coming to see the system. We have some delegations, one of them was even like 10 or 15 people. We are willing and will be willing to host any size of group that will be able to see what we do.
Unidentified Analyst: And there could be multiple people from a single site, I would assume. So that makes sense.
Erez Meltzer: Absolutely.
Unidentified Analyst: And then you mentioned the sales team, a direct sales force in the U.S. I’m wondering about the size of that sales team, the timing of the onboarding of your initial sales reps and then how we should be thinking about the impact to sales and marketing expense going forward for modeling purposes.
Erez Meltzer: Let’s start with the first question. So as I’ve indicated, we are building the team as we speak. We mentioned in the past that we are in the final process of conclude and complete the full action plan or execution plan of the deployment in the U.S. Part of what — of this, I’ve shared with earlier today. And the full, I would say, more detailed plan including numbers and further indications will be presented in the Investors Day that we’re planning to the end of September. By then, we are going to have probably most of the team already ready to do the work. We are planning the kickoff early October In the U.S. A few of the people have already engaged and working in the U.S. So I think that more of this, you will be able to hear — we are talking, by the way, on the September 22 at NASDAQ to have the Investors Day that we’re planning. And more details to come on this.
Unidentified Analyst: Excellent. Looking forward to that Investor Day. And then lastly for us, you’re collecting a lot of clinical and some real-world data. I’m wondering if you’ll create some kind of registry to kind of capture all of that.
Erez Meltzer: The answer is yes. Part of it will be shown and presented in our website. Everything based on what is allowed, what we can, it will be based on regulation related to this disclosure. We are also in the process of preparing all the clinical data collected and prepare the paper that we’re going to release. So this is actually, at the same time that we do all the commercial deployment, we’re going to make a lot of efforts and emphasize the clinical side of what we are doing. I think that I’ve shared a little bit today that, as you know, in the U.S. we are allowed right now to do the MSK, but in the rest of the world we do chest, abdomen and other anatomies. So both in Israel and in Morocco, we have already tested and scanned humans in the other anatomies used. So basically, this is the plan that we move forward in order to enhance our ability to do the clinical — to provide the clinical data and explore the opportunities for the future intended use.
Operator: Thank you. This is all the time we have for questions. Thank you for your participation in today’s conference. You may disconnect. Have a great day.
